|
pubmed:otherAbstract |
PIP: To investigate the effect of medroxyprogesterone acetate therapy upon the immune response and endogenous status of patients with primary or recurrent endometrial adenocarcinoma, 8 patients were treated with progestin therapy as inpatients for 33-80 days. Patients were studied intermittently for up to 72 months. Serum protein electrophoresis during treatment showed no change in protein pattern. In all 8 patients, there was a suppression of pituitary gonadotrophin. There was no evidence that the adenocarcinomas were suppressed by either an immunologic mechanism or by the variation in endogenous hormone production. Investigation should be continued to study the effects of medroxyprogesterone acetate on the cellular level.
|
